PBI-Gordon Companies Acquires TriviumVet, Expands Innovative Pet Health Portfolio

PBI-Gordon Companies, Inc., an organization that inspires innovations for green spaces, pets and people, has announced the strategic acquisition of TriviumVet, a leading research and development company advancing innovative treatments for chronic conditions in cats and dogs. The move is the largest transaction in the company’s 77-year history and includes the addition of an innovative new product, Felycin-CA1, to the PRN Pharmacal portfolio of products.

“Driven by the powerful belief that the pets we love deserve the same advanced care and innovation as people, we came together with a common purpose, to create and deliver cutting-edge solutions to improve the quality of life for cats and dogs,” said Louise Grubb, Co-Founder of TriviumVet. “By partnering with PBI-Gordon, we will be able to ensure that our innovative products and pipeline will have global reach that benefits pets and their owners around the world.”

Felycin-CA1 (Sirolimus Delayed-Release Tablets) is the first U.S Food and Drug Administration (FDA)-conditionally approved drug for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM), which affects as many as one in seven cats.

“Feline hypertrophic cardiomyopathy (HCM) is one of the most common and life-threatening diseases in cats,” said Dr. Stuart Fitzgerald, MVB, MANZCVS. “Increasing awareness, education, and access to treatment can contribute to earlier diagnosis and better management—ultimately helping cats live longer, healthier lives.”

Felycin-CA1 will be available for veterinary customers to order by August of this year. To ensure customer engagement while building pet owner awareness for a successful product launch, PRN Pharmacal will expand its team by hiring over 50 additional employees.

In addition to Felycin-CA1, TriviumVet has a robust pipeline of therapeutics targeting some of the most pressing conditions including feline chronic kidney disease, as well as pain management and gastric ulcers in canines. These groundbreaking solutions not only address unmet needs but also empower pet owners to proactively enhance the lives of their pets.

“This acquisition represents a significant milestone in the treatment of HCM and enhances the ability to grow our companion animal health pharmaceutical business with new innovative products,” said Stephen Clifford, president and CEO of PBI-Gordon Companies. “With TriviumVet, we have acquired a complete research and development organization with a complementary development philosophy that values precision, unmet need identification, and cross-functional collaboration between scientific, regulatory and commercial teams. Together we will drive innovation and deliver solutions that will shape a healthier future for pets and their owners worldwide. This transaction is a clear demonstration of our commitment to growing PBI-Gordon and investing in the future.”

Louise Grubb will remain on as managing director of TriviumVet, which will continue to work as an independent, yet integrated team in Waterford, Ireland as a fourth subsidiary of PBI Gordon Companies. The team will report to PBI-Gordon Companies’ chief operating officer Jackie Applegate.